Progress in treatment of clinical stage N2 non-small cell lung cancer / 国际肿瘤学杂志

ABSTRACT

Although the optimal treatment protocol for clinical N2-stage non-small cell lung cancer (NSCLC) is still uncertain, the recommended standard treatment protocol goes to radical concurrent chemora diotherapy. Concurrent chemoradiotherapy after induction chemotherapy is not superior to standard concurrent chemoradiotherapy. Neoadjuvant concurrent chemoradiotherapy followed by pulmonary lobectomy can improve overall survival ratio comparaed with preoperative neoadjuvant concurrent chemoradiotherapy. The role of concurrent chemoradiotherapy followed by consooldation chemotherapy is still controversial. Gefitinib or erlotinib failed to bring about the survival benefit from the maintenance treatment after concurrent chemoradiotherapy. Prophylactic cranial irradiation play a role merely in decreasing the risk of brain metastases, but not in the improvement of overall survival.